Biocytogen’s Post

View organization page for Biocytogen, graphic

9,973 followers

🌟Exploring the Potential of CD40L Antagonists in Autoimmune Disease🔬 Exciting Developments in Autoimmune Therapy! CD40 ligand (CD40L), which is transiently expressed on activated T cells and is crucial for both antibody and cell-mediated immune responses, has been the focus of over 30 years of research aimed at developing effective inhibitors. Several CD40L antagonists currently in clinical trials have shown promising therapeutic benefits for both organ-specific and systemic autoimmune diseases, with the potential to impact a broader range of immune-mediated inflammatory conditions, including inflammatory bowel disease and rheumatoid arthritis. At Biocytogen, we're dedicated to advancing these developments. Our humanized mouse models of CD40L offer a crucial human genetic context for drug testing. Additionally, we've created fully human antibodies targeting CD40L with our proprietary RenMice platforms, driving the development of innovative therapies.💡Contact us to learn how our advanced products and services can enhance your research! B-hCD40L mice: https://lnkd.in/eeWwQaM3 B-hCD40/hCD40L mice: https://lnkd.in/eFd3sEmv Read more: https://lnkd.in/eNDkRkwA #AutoimmuneDisease #Immunotherapy #ClinicalTrials #HealthcareInnovation #Biotech

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics